Rituximab

Rituximab Maintenance Prolongs PFS in Patients With CLL

Rituximab Maintenance Prolongs PFS in Patients With CLL

By

New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

By

For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

ASCO: New strategies promising for chronic-lymphocytic leukemia and non-Hodgkin lymphoma

Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma.

Targeting CD20 in chronic lymphocytic leukemia

Targeting CD20 in chronic lymphocytic leukemia

[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.

Infusion times for rituximab

Infusion times for rituximab

By

Other oncology nurses have mentioned to me that they infuse rituximab (Rituxan) over 90 minutes. Are there references for this?

FDA Update November/December 2012

Paclitaxel protein-bound particles for injectable suspension, 90-minute infusion of rituximab, omacetaxine mepesuccinate receive FDA approval

GVHD in pediatric HSCT patients: Clinical trials for Rituximab

GVHD in pediatric HSCT patients: Clinical trials for Rituximab

The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs